



US 20080319184A1

(19) **United States**(12) **Patent Application Publication** (10) **Pub. No.: US 2008/0319184 A1**

Miller et al.

(43) **Pub. Date: Dec. 25, 2008**(54) **USES OF DINUCLEOTIDE POLYPHOSPHATE DERIVATIVES****Publication Classification**(76) Inventors: **Andrew David Miller**, London (GB); **Michael Wright**, London (GB); **Julian Alexander Tanner**, Hong Kong (HK); **Natalya Lozovaya**, London (GB)(51) **Int. Cl.**
C07H 21/02 (2006.01)
(52) **U.S. Cl.** 536/26.26Correspondence Address:
SUZANNAH K. SUNDBY
SMITH, GAMBRELL & RUSSEL, LLP
1130 Connecticut Avenue, NW, Suite 1130
WASHINGTON, DC 20036 (US)(57) **ABSTRACT**

The present invention provides the use of analogues and derivatives of dinucleoside polyphosphates with formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in one or more of: the treatment of ischemia, inducing ischemic tolerance, modulating cerebral ischemia, to delay the onset of a hypoxic depolarisation stage when ischemic events are initiated; as a neurological protection agent; as a tissue protection agent; the treatment of pain; and the treatment of inflammation, wherein X, is selected from wherein X¹ and X² are independently selected from H, Cl, Br and F; each Y is independently selected from S and O; each Z is independently selected from —CX³X⁴—, —NH—, —O—; wherein X³ and X⁴ are selected from H, Cl, Br and F; B1 and B2 are independently selected from adenine, guanine, xanthine, thymine, uracil, cytosine and inosine; S₁ and S₂ are independently selected from ribose, open chain ribose, 2'-deoxyribose, 3'-deoxyribose and arabinofuranoside. V is selected from 0, 1, 2, 3, 4 and 5; W is selected from 0, 1, 2, 3, 4 and 5; and V plus W is an integer from 2 to 6.


(21) Appl. No.: 11/883,661

(22) PCT Filed: Feb. 1, 2006

(86) PCT No.: PCT/GB06/00343

§ 371 (c)(1),
(2), (4) Date: Aug. 27, 2008(30) **Foreign Application Priority Data**

Feb. 3, 2005 (GB) 0502250.4






Figure 1




Figure 2




Figure 3




Figure 4




Figure 5 a





Figure 5 b





Figure 5 c